http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Nasibeh Amirzagar,Shahriar Nafissi,Abbas Tafakhori,Amirhossein Modabbernia,Aliakbar Amirzargar,Majid Ghaffarpour,Bahaddin Siroos,Mohammad Hossein Harirchian 대한신경과학회 2015 Journal of Clinical Neurology Vol.11 No.2
Background and Purpose Te aim of this study was to determine the efcacy and tolerability of granulocyte colony-stimulating factor (G-CSF) in subjects with amyotrophic lateralsclerosis (ALS). Methods Forty subjects with ALS were randomly assigned to two groups, which received either subcutaneous G-CSF (5 μg/kg/q12h) or placebo for 5 days. Te subjects were then followed up for 3 months using the ALS Functional Rating Scale-Revised (ALSFRS-R), manualmuscle testing, ALS Assessment Questionnaire-40, and nerve conduction studies. CD34+/CD133+ cell count and monocyte chemoattractant protein-1 (MCP-1) levels were evaluated atbaseline. Results Te rate of disease progression did not difer signifcantly between the two groups. Te reduction in ALSFRS-R scores was greater in female subjects in the G-CSF group than intheir counterparts in the placebo group. Tere was a trend toward a positive correlation between baseline CSF MCP-1 levels and the change in ALSFRS-R scores in both groups (Spearman’s ρ=0.370, p=0.070). Conclusions With the protocol implemented in this study, G-CSF is not a promising optionfor the treatment of ALS. Furthermore, it may accelerate disease progression in females.